ATR-IN-23 manufacturers
- ATR-IN-23
-
- $1980.00
-
2026-05-11
- CAS:2923800-62-6
- Purity:
- Supply Ability: 10g
|
| | ATR-IN-23 Basic information |
| Product Name: | ATR-IN-23 | | Synonyms: | ATR-IN-23;1H-Benzimidazol-2-amine, N-methyl-1-[4-[(3R)-3-methyl-4-morpholinyl]-7-(methylsulfonyl)thieno[3,2-d]pyrimidin-2-yl]- | | CAS: | 2923800-62-6 | | MF: | C20H22N6O3S2 | | MW: | 458.56 | | EINECS: | | | Product Categories: | | | Mol File: | 2923800-62-6.mol |  |
| | ATR-IN-23 Chemical Properties |
| Boiling point | 765.622±70.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.577±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | pka | 5.767±0.10(predicted) |
| | ATR-IN-23 Usage And Synthesis |
| Uses | ATR-IN-23 (Compound 34) is a potent and selective ATR inhibitor with an IC50 of 1.5 nM. ATR-IN-23 has potent antiproliferative effects on LoVo cells and synthetic lethality on HT-29 cells, and can be used in the study of DNA damage response (DDR)-deficient cancers[1]. | | in vivo | ATR-IN-23 shows acute toxicity at a maximum concentration of 2000 mg/kg and possesses moderate safety in ICR mice[1].
ATR-IN-23 (50 mg/kg; once a day or twice a day; p.o.; 21 days) exhibits moderate antitumor efficacy in BALB/c nude mice[1]. | Animal Model: | BALB/c nude mice[1] | | Dosage: | 50 mg/kg | | Administration: | p.o., once a day or twice a day for 21 consecutive days, dissolved in a solution of DMSO (10%), solutol (10%), and saline (80%) | | Result: | Exhibited moderate antitumor efficacy, with a tumor growth inhibition (TGI) value of 55% at dosages of 50 mg/kg twice a day. |
| | References | [1] Duan Y, et al. Discovery of Thieno[3,2-d]pyrimidine derivatives as potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) kinase. Eur J Med Chem. 2023 Jul 5;255:115370. DOI:10.1016/j.ejmech.2023.115370 |
| | ATR-IN-23 Preparation Products And Raw materials |
|